The FDA’s accelerated approval route has delivered important new drugs to patients quicker, but is opaque and plagued by inconsistencies, says ICER.

Eli Lilly’s ACHIEVE-4 trial results for oral GLP-1 Foundayo set up a filing in diabetes, and provide safety data sought by the FDA.

Eli Lilly’s recently approved obesity pill Foundayo cut the risk of cardiovascular events like heart attack and stroke by 16% versus a form of insulin,

A review of clinical data on amyloid-targeting Alzheimer’s therapies has found absent or trivial efficacy, but is facing pushback from some experts.

Omnicom Health has stamped its mark on the recently acquired FCB Health New York, rebranding the ad agency as Olixir New York in the aftermath